BR0315411A - Fator para metástase e empregos deste - Google Patents

Fator para metástase e empregos deste

Info

Publication number
BR0315411A
BR0315411A BR0315411-4A BR0315411A BR0315411A BR 0315411 A BR0315411 A BR 0315411A BR 0315411 A BR0315411 A BR 0315411A BR 0315411 A BR0315411 A BR 0315411A
Authority
BR
Brazil
Prior art keywords
factor
metastasis
polypeptide
amino acid
extracellular matrix
Prior art date
Application number
BR0315411-4A
Other languages
English (en)
Inventor
Anke Klippel-Giesel
Joerg Kaufmann
Rolf Schwarzer
Original Assignee
Atugen Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Atugen Ag filed Critical Atugen Ag
Publication of BR0315411A publication Critical patent/BR0315411A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"FATOR PARA METáSTASE E EMPREGOS DESTE". A presente invenção refere-se a um ácido nucléico codificando para um fator envolvido em um processo biológico, pelo qual o processo é um processo regulado por trilha de PI 3-cinase, preferivelmente um processo selecionado do grupo compreendendo metabolismo de glicose, processos de privação de glicose e aminoácido, diabetes, cicatrização de ferimento, resposta ao estresse, apoptose, metástase, tumorigênese, migração de célula, motilidade de célula em matriz extracelular e desenvolvimento de célula em matriz extracelular, e o fator é um polipeptídeo compreendendo uma seq³ência de acordo com SEQ ID NO: 1 ou um polipeptídeo tendo uma seq³ência de acordo com as entradas no banco de dados gi 9506687 ou NP_061931, preferivelmente NP_061931,1.
BR0315411-4A 2002-10-18 2003-10-20 Fator para metástase e empregos deste BR0315411A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02023384 2002-10-18
PCT/EP2003/011604 WO2004035615A2 (en) 2002-10-18 2003-10-20 Factor involved in metastasis and uses thereof

Publications (1)

Publication Number Publication Date
BR0315411A true BR0315411A (pt) 2005-08-16

Family

ID=32103889

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0315411-4A BR0315411A (pt) 2002-10-18 2003-10-20 Fator para metástase e empregos deste

Country Status (19)

Country Link
US (2) US20060240022A1 (pt)
EP (2) EP1551868B1 (pt)
JP (2) JP4820092B2 (pt)
KR (1) KR101154130B1 (pt)
CN (1) CN100564524C (pt)
AT (1) ATE420102T1 (pt)
AU (2) AU2003278112A1 (pt)
BR (1) BR0315411A (pt)
CA (1) CA2501333A1 (pt)
CY (1) CY1110313T1 (pt)
DE (1) DE60325754D1 (pt)
DK (1) DK1551868T3 (pt)
ES (1) ES2319891T3 (pt)
IL (1) IL167801A (pt)
MX (1) MXPA05004134A (pt)
PT (1) PT1551868E (pt)
SI (1) SI1551868T1 (pt)
WO (1) WO2004035615A2 (pt)
ZA (1) ZA200502483B (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7405292B2 (en) * 2002-02-19 2008-07-29 The Children's Hospital Of Philadelphia Cellular genes regulated by HIV-1 infection and methods of use thereof
ES2280826T5 (es) 2002-08-05 2017-08-03 Silence Therapeutics Gmbh Nuevas formas adicionales de moléculas de ARN de interferencia
JP4820092B2 (ja) * 2002-10-18 2011-11-24 サイレンス・セラピューティクス・アーゲー 転移のための新規な因子及びその使用
AU2005277508B2 (en) 2004-08-16 2011-04-14 Quark Pharmaceuticals, Inc Therapeutic uses of inhibitors of RTP801
CN100357323C (zh) * 2006-01-05 2007-12-26 清华大学 一种细胞迁移相关蛋白及其编码基因与应用
NL2000439C2 (nl) 2006-01-20 2009-03-16 Quark Biotech Therapeutische toepassingen van inhibitoren van RTP801.
US7825099B2 (en) 2006-01-20 2010-11-02 Quark Pharmaceuticals, Inc. Treatment or prevention of oto-pathologies by inhibition of pro-apoptotic genes
FR2898908A1 (fr) 2006-03-24 2007-09-28 Agronomique Inst Nat Rech Procede de preparation de cellules aviaires differenciees et genes impliques dans le maintien de la pluripotence
GB2450840B (en) * 2006-05-11 2010-12-29 Quark Pharmaceuticals Inc Screening Systems Utilizing RTP801
US7872119B2 (en) 2007-02-26 2011-01-18 Quark Pharmaceuticals, Inc. Inhibitors of RTP801 and their use in disease treatment
EP2326351B1 (en) 2008-08-19 2017-12-27 Nektar Therapeutics Conjugates of small-interfering nucleic acids
US8916693B2 (en) 2009-09-17 2014-12-23 Nektar Therapeutics Monoconjugated chitosans as delivery agents for small interfering nucleic acids
WO2014043289A2 (en) 2012-09-12 2014-03-20 Quark Pharmaceuticals, Inc. Double-stranded oligonucleotide molecules to ddit4 and methods of use thereof

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1493825A3 (en) 1990-06-11 2005-02-09 Gilead Sciences, Inc. Method for producing nucleic acid ligands
AU743469C (en) 1996-08-30 2004-02-12 Rolf Bald Mirror-symmetrical selection and evolution of nucleic acids
US5849902A (en) 1996-09-26 1998-12-15 Oligos Etc. Inc. Three component chimeric antisense oligonucleotides
US6958239B2 (en) 1996-11-21 2005-10-25 Oligos Etc Inc. Three component chimeric antisense oligonucleotides
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
AU3751299A (en) 1998-04-20 1999-11-08 Ribozyme Pharmaceuticals, Inc. Nucleic acid molecules with novel chemical compositions capable of modulating gene expression
US5958773A (en) * 1998-12-17 1999-09-28 Isis Pharmaceuticals Inc. Antisense modulation of AKT-1 expression
DE19956568A1 (de) 1999-01-30 2000-08-17 Roland Kreutzer Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
WO2000077022A1 (en) * 1999-06-11 2000-12-21 Human Genome Sciences, Inc. 50 human secreted proteins
US6133032A (en) * 1999-09-09 2000-10-17 Isis Pharmaceutical Inc. Antisense modulation of PI3 kinase p110 beta expression
WO2003070918A2 (en) 2002-02-20 2003-08-28 Ribozyme Pharmaceuticals, Incorporated Rna interference by modified short interfering nucleic acid
IL151928A0 (en) 2000-03-30 2003-04-10 Whitehead Biomedical Inst Rna sequence-specific mediators of rna interference
US6673545B2 (en) * 2000-07-28 2004-01-06 Incyte Corporation Prostate cancer markers
AU2002220920A1 (en) * 2000-12-08 2002-06-18 Oxford Biomedica (Uk) Limited Method for identification of genes involved in specific diseases
WO2003010205A1 (en) * 2001-07-26 2003-02-06 Duke University Medical Center Genes induced by hypoxia
EP1565581B1 (en) * 2002-08-20 2011-08-10 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of cervical cancer
JP4820092B2 (ja) * 2002-10-18 2011-11-24 サイレンス・セラピューティクス・アーゲー 転移のための新規な因子及びその使用
AU2005277508B2 (en) * 2004-08-16 2011-04-14 Quark Pharmaceuticals, Inc Therapeutic uses of inhibitors of RTP801

Also Published As

Publication number Publication date
KR101154130B1 (ko) 2012-06-12
WO2004035615A3 (en) 2004-06-03
ES2319891T3 (es) 2009-05-14
EP2072619A1 (en) 2009-06-24
JP2011125339A (ja) 2011-06-30
AU2003278112A1 (en) 2004-05-04
PT1551868E (pt) 2009-04-06
WO2004035615A2 (en) 2004-04-29
CN100564524C (zh) 2009-12-02
CN1705746A (zh) 2005-12-07
ATE420102T1 (de) 2009-01-15
DE60325754D1 (de) 2009-02-26
CY1110313T1 (el) 2015-01-14
MXPA05004134A (es) 2005-10-05
DK1551868T3 (da) 2009-04-20
JP2006520183A (ja) 2006-09-07
EP1551868A2 (en) 2005-07-13
JP4820092B2 (ja) 2011-11-24
US20100285038A1 (en) 2010-11-11
US20060240022A1 (en) 2006-10-26
KR20050056244A (ko) 2005-06-14
SI1551868T1 (sl) 2009-06-30
IL167801A (en) 2012-10-31
AU2010246370A1 (en) 2010-12-16
ZA200502483B (en) 2005-11-30
EP1551868B1 (en) 2009-01-07
CA2501333A1 (en) 2004-04-29

Similar Documents

Publication Publication Date Title
CY1110313T1 (el) Παραγοντας που εμπλεκεται στη μετασταση και οι χρησεις του
Joester et al. Evidence for combinatorial variability of tenascin-C isoforms and developmental regulation in the mouse central nervous system
Valenzuela et al. The salivary apyrase of the blood-sucking sand fly Phlebotomus papatasi belongs to the novel Cimex family of apyrases
Zhou et al. Evidence that HetR protein is an unusual serine-type protease
Butenko et al. Plant peptides in signalling: looking for new partners
Staub et al. WW domains
Ludwig et al. Characterization of the human adenylyl cyclase gene family: cDNA, gene structure, and tissue distribution of the nine isoforms
Brophy et al. The small heat shock-related protein–20 is an actin-associated protein
Kadalayil et al. Adjacent GATA and κB-like motifs regulate the expression of a Drosophila immune gene
Hara et al. Heterodimer formation between the antimicrobial peptides magainin 2 and PGLa in lipid bilayers: a cross-linking study
Paskewitz et al. The hemolymph proteome of Anopheles gambiae
Jilek et al. Biosynthesis of a D-amino acid in peptide linkage by an enzyme from frog skin secretions
Yonemura et al. Protein composition of silk filaments spun under water by caddisfly larvae
Andersen et al. A new secreted insect protein belonging to the immunoglobulin superfamily binds insulin and related peptides and inhibits their activities
Estévez-Lao et al. Cardioacceleratory function of the neurohormone CCAP in the mosquito Anopheles gambiae
CA2511873A1 (en) Modulation of protein functionalities
Razpotnik et al. A new phospholipase A2 isolated from the sea anemone Urticina crassicornis–its primary structure and phylogenetic classification
Fitzgerald et al. WARP is a new member of the von Willebrand factor A-domain superfamily of extracellular matrix proteins
Brown et al. Unwinding of the substrate transmembrane helix in intramembrane proteolysis
Moser et al. LE-PAS, a novel Arnt-dependent HLH-PAS protein, is expressed in limbic tissues and transactivates the CNS midline enhancer element
Ni et al. Effects of titanium dioxide nanoparticles on the synthesis of fibroin in silkworm (Bombyx mori)
Heintzelman et al. Cloning of a secretory gelsolin from Drosophila melanogaster
ATE61631T1 (de) Gen fuer ein protein mit insektizider wirkung.
Huang et al. The neuronal POU transcription factor Brn-2 interacts with Jab1, a gene involved in the onset of neurodegenerative diseases
Miano et al. Identification and up-regulation of three small heat shock proteins in summer and winter diapause in response to temperature stress in Pieris melete

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25D Requested change of name of applicant approved

Owner name: SILENCE THERAPEUTICS AG (DE)

Free format text: NOME ALTERADO DE: ATUGEN AG.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 10A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2256 DE 01/04/2014.